Screening for pancreatic neoplasia in high-risk individuals: Who, What, When, How?

Research output: Contribution to journalArticlepeer-review

Abstract

Pancreatic cancer (PC) is a highly lethal disease. Most symptomatic, clinically detected PCs are advanced and not curable. Indeed, the estimated 5-year survival rate is 4%, which is attributable to late diagnosis and low resection rate. Screening of high-risk individuals and early detection of small PCs and precursor lesions might improve the outcome if curative therapy could be offered in the presymptomatic stage. This article summarizes the available published data and preliminary results and discusses the different approaches to screening for pancreatic neoplasia at 2 university-based programs in the United States.

Original languageEnglish (US)
Pages (from-to)S46-S48
JournalClinical Gastroenterology and Hepatology
Volume3
Issue number7 SUPPL.
DOIs
StatePublished - Jul 2005

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Screening for pancreatic neoplasia in high-risk individuals: Who, What, When, How?'. Together they form a unique fingerprint.

Cite this